---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-26-000049"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2026-07-27T20:06:43+00:00"
generated_at: "2026-07-27T20:08:25.447384+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific approves 2026 restructuring plan with $700M-$800M pre-tax charges

## Summary
- Board approved 2026 Restructuring Plan on July 21, 2026; expected to be substantially completed by end of 2029.
- Estimated total pre-tax charges of $700M-$800M, with $600M-$700M in cash outlays; annual pre-tax expense reduction of ~$500M.
- Charges include transfer costs ($300M-$350M), termination benefits ($275M-$300M), and other costs ($125M-$150M).
- Headcount reductions expected, but new jobs created in growth areas; savings to be reinvested in strategic growth initiatives.
- Activities include supply chain optimization, transferring production lines, and functional transformation.

## SEC filing metadata
- accession: 0000885725-26-000049
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2026-07-27T20:06:43+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572526000049/0000885725-26-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572526000049/bsx-20260721.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-26-000049
- JSON: https://secwatch.observer/filing/0000885725-26-000049.json
- Plain text: https://secwatch.observer/filing/0000885725-26-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.